Cancer Research

microRNA
#Collaboration #Lipid based nanoparticle (LNP) #Oncology #Partnership #Quantoom Biosciences #RNA

Quantoom and MSK unite on personalised cancer therapies

Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002.  Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More

#Cancer Research #News

Vials for medical research
#Cancer research #Great Ormond Street Hospital

Great Ormond Street Hospital Charity joins cancer research consortium

Great Ormond Street Hospital Charity (GOSH Charity) has joined Cancer Research Horizons and LifeArc as a core partner to help drive innovation in children’s and young people’s cancer treatment, drug discovery consortium C-Further has announced.  C-Further is an international consortium of drug discovery and development researchers, clinicians,… Read More

#Cancer Research #News

#Cancer research #Drug discovery #Leukaemia

CAR-T therapy could be effective cancer treatment, study suggests

CAR-T therapy could be an effective treatment for leukaemia, preclinical data published by biotechnology company Gyala Therapeutics suggests.  The data emerged from a study highlighting the use of CAR-T therapy, GYA01, to treat acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). The study is the… Read More

#Cancer Research #News

Lung cancer
#BioNTech #Bristol Myers Squibb #Lung cancer #Oncology #Phase II trial

Bispecific antibody trial shows encouraging antitumour activity

BioNTech and Bristol Myers Squibb have revealed global interim Phase II data for their PD-L1xVEGF-A bispecific antibody pumitamig in patients with extensive-stage small cell lung cancer (ES-SCLC) which shows encouraging antitumour activity.  The data for pumitamig plus chemotherapy showed a 76.3% confirmed objective response rate (cORR), 100%… Read More

#Cancer Research #News

Vaccine research
#Cancer drug targets #Oncology #Proteomics #The Institute of Cancer Research

Redox proteomics reveals potential target for cancer therapies

Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies.  The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later… Read More

#Cancer Research #Editor's Choice #News

Colon cancer
#Colorectal cancer #Larkspur Biosciences #Oncology #Preclinical development #Solid tumours

First degrader of lipid kinase PIP4K2C shows promise in colon cancer

Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.   The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More

#Cancer Research #News

Long Covid concept
#Covid-19 #Genetics / genomics #Long Covid #Oncology #Spatial biology

Enhancing cancer and long Covid research

Genomic and spatial technologies are helping to bring greater insights into cancer and diseases such as long Covid, writes Jack DiGiovanna, Chief Science Officer at Velsera. Emerging genomic and spatial technologies are transforming research on complex diseases like cancer and long Covid. These advancements offer unprecedented precision in diagnostics and… Read More

#Cancer Research #Exclusive Content

Hepatitis virus
#Oncology #Oncolytic virus #Personalised medicine #The Institute of Cancer Research #Virology

Combining viruses with targeted cancer drugs boosts response

Two studies have uncovered how combining a reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.  Researchers at The Institute of Cancer Research, London, have shown that this combination involving virotherapy can… Read More

#Cancer Research #Editor's Choice #News

T cell attacking a cancer cell
#Antibodies #Immunotherapy #Oncology #Phase I trial #Rockefeller University

Immunotherapy drug eliminates aggressive cancers

A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.  CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.  … Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#Autophagy #Cancer Research UK #KRAS #Oncology #Pancreatic cancer

Autophagy disruption provides clues to cancer development

Scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer.   The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.   The research was… Read More

#Cancer Research #News

Test for KRAS mutation
#Bayer #KRAS #Kumquat Biosciences #Oncology #Precision medicine

Bayer and Kumquat collaborate on precision oncology

Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities. … Read More

#Business & Investment #Cancer Research #News

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News